Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesAge, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: A cost-effectiveness analysis
Vaccine , 05/29/09
Smith KJ et al. - Single-dose PPV is worth considering in patients aged 65–80 from clinical and economic standpoints. Revaccination strategies for the elderly are less cost-effective, particularly when prior vaccination and vaccine tolerance are considered.
Related Articles
CDC Survey Shows Gains in Overall Adolescent Vaccination Rates for 2008. But Majority Still Lack Immunizations for Tdap, MCV4
American Family Physician, 10/23/09
Relevance Score: 99%
A survey of adolescent experiences of human papillomavirus vaccination in the Manchester study
British Journal of Cancer, 10/09/09
Relevance Score: 97%
One Dose of H1N1 Vaccine Immunogenic in High Percentage of Youth Ages 10 to 17. Younger Children Likely Will Need Two Doses
American Family Physician, 10/05/09
Relevance Score: 97%
Human Papillomavirus Vaccine Uptake, Predictors of Vaccination, and Self-Reported Barriers to Vaccination
Journal of Women's Health, 10/05/09
Relevance Score: 96%
H1N1 Vaccine Deliveries Begin. Early Doses to Arrive This Week
American Family Physician, 10/07/09
Relevance Score: 95%
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia
Current Medical Research and Opinion, 12/18/09
Costs of hospital-based methadone maintenance treatment in HIV/AIDS control among injecting drug users in Indonesia
Health Policy, 12/16/09
Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
Cost Effectiveness and Resource Allocation, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor